Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | PHASE1 | RECRUITING | 336 | — | — | Jun 9, 2022 | Dec 10, 2027 | Dec 5, 2025 | 25 | United States |
| Arm | Type | Description |
|---|---|---|
| Phase 1/1B | EXPERIMENTAL | Dose Escalation/Evaluation |
| Phase 1b Sub-studies 1-4 | EXPERIMENTAL | - |
| Phase 1b Sub-study 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRTX1719 | DRUG | MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days |
Inclusion Criteria * Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. * Unresectable or metastatic disease. * Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-s...